Risk of Recurrent Plasmodium vivax Malaria after Chloroquine Plus Low-Dose Primaquine in Pakistan: A Prospective Cohort Study
Kamala Thriemer(Charles Darwin University), M Beg(Aga Khan University Nairobi), Amna Ibrahim(Beni-Suef University), Ric N. Price(Charles Darwin University), Sarah Auburn(Centre for Human Genetics), Julie Healer(The University of Melbourne), Ivo Müeller(The University of Melbourne), Benedikt Ley(Charles Darwin University), Rhea J. Longley(Walter and Eliza Hall Institute of Medical Research), Nasreen A. Syed(Aga Khan University), Grant Lee(Charles Darwin University), Hellen Mnjala(Charles Darwin University), Robert J. Commons(Charles Darwin University), Umair Ali(Islamia University of Bahawalpur), Bushra Qurashi(Aga Khan University), F. Jabbar(Aga Khan University), Khuda Dost(Aga Khan University), Shane Zehra(Aga Khan University), Tariq Mehmood(Aga Khan University), Abdul Hameed Khaskheli(Directorate General of Health Services), Mushtaque Ahmed Shah(Directorate General of Health Services), Najia Ghanchi(Aga Khan University), Sajida Dhari(Directorate General of Health Services), Ali Raza(Aga Khan University Nairobi), Edwin Sutanto(Charles Darwin University), Zainab Rafeew Adam(Aga Khan University Hospital), Anjana Rai
Cited by 0
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study
|The Lancet|2019|422
Genome-wide and fine-resolution association analysis of malaria in West Africa
|Nature Genetics|2009|393
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350